Biotechnology and Pharmaceutical Industry Consulting

BioPharma Consulting Services LLC (BPCS) provides strategic advice and consulting services to the biotechnology and pharmaceutical industry, primarily for small to medium sized biotechnology and pharmaceutical companies. With broad-based experience, a small dedicated team and a network of experienced industry professionals, BPCS is well-positioned to provide strategic and operational expertise to companies facing challenges in the clinical development, regulatory approval and commercialization of breakthrough therapeutics. Through its extensive multi-disciplinary network, BPCS has the capability to support and manage almost all aspects of drug development. BPCS can assemble virtual drug development teams and assist in both outsourcing and recruitment of internal staff. This has provided a number of start-up companies an efficient and cost-effective approach to jump-starting clinical development even before recruiting internal staff. We encourage you to contact us to learn more about our services.

Our philosophy is that solid science throughout the development process translates into better go/no go decisions, more collaborative relationships with regulatory authorities and, ultimately, more successful and cost-effective product development.

Located in the Seattle, Washington area, BioPharma Consulting Services LLC (BPCS) was founded in 2002 by Dr. Richard Stead in order to meet the growing needs of emerging and established companies developing biotechnology or pharmaceutical products. BPCS has the flexibility and responsiveness to meet specific requirements of small biotech companies. BPCS provides a range of services from shorter term, focused evaluation of clinical/regulatory strategy or in-licensing opportunities to longer term strategic and/or operational relationships.

BPCS has served clients in several therapeutic areas and has directed the clinical development programs of a number of companies including interactions with regulatory agencies as well as the initiation and refocusing of their clinical trials programs. In addition, BPCS has been directly involved in the management and fund-raising for smaller privately held companies. Dr. Stead has served as Acting Chief Medical Officer and served on the senior management for a number of emerging biotechnology companies. He serves on the Board of Directors of Affimed Therapeutics AG, a privately held biotechnology company based in Heidelberg, Germany that develops next generation antibody therapeutics.